Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Cantor Fitzgerald analyst Carter Gould maintains Amgen (NASDAQ:AMGN) with a Neutral and raises the price target from $305 to...
Wall Street bounced back Wednesday after Tuesday's sharp selloff in AI-driven stocks, as investors bought the dip amid soli...
Morgan Stanley analyst Terence Flynn maintains Amgen (NASDAQ:AMGN) with a Equal-Weight and lowers the price target from $333...
Wells Fargo analyst Mohit Bansal maintains Amgen (NASDAQ:AMGN) with a Overweight and raises the price target from $280 to $300.
2025 GuidanceFor the full year 2025, the Company expects:Total revenues in the range of $35.8 billion to $36.6 billion.On a GAA...
Amgen Inc.Reconciliation of GAAP EPS Guidance to Non-GAAP EPS Guidance for the Year Ending December 31, 2025(Unaudited) G...
Amgen (NASDAQ:AMGN) raises FY2025 Adj EPS guidance from $20.20-$21.30 to $20.60-$21.40 vs $21.03 analyst estimate..
Amgen (NASDAQ:AMGN) reported quarterly earnings of $5.64 per share which beat the analyst consensus estimate of $5.01 by 12.49 ...
